Jonathan Young Sells 10,000 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $28.03, for a total transaction of $280,300.00. Following the transaction, the chief operating officer now directly owns 218,083 shares of the company’s stock, valued at approximately $6,112,866.49. This trade represents a 4.38 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Jonathan Young also recently made the following trade(s):

• On Tuesday, December 10th, Jonathan Young sold 2,503 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total transaction of $77,067.37.
• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total value of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The stock was sold at an average price of $31.57, for a total value of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total value of $1,206,000.00.

Akero Therapeutics Stock Performance

Shares of AKRO opened at $26.61 on Wednesday. Akero Therapeutics, Inc. has a 1 year low of $15.32 and a 1 year high of $37.00. The stock has a market capitalization of $1.86 billion, a PE ratio of -7.10 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The stock has a 50-day simple moving average of $30.39 and a 200-day simple moving average of $27.97.

Akero Therapeutics (NASDAQ:AKRO) last issued its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15). On average, analysts predict that Akero Therapeutics, Inc. will post -3.96 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AKRO. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research report on Monday, November 18th. Citigroup initiated coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price objective for the company. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $46.83.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors have recently modified their holdings of AKRO. Exome Asset Management LLC acquired a new stake in Akero Therapeutics in the third quarter valued at $2,212,000. Barclays PLC raised its position in shares of Akero Therapeutics by 127.9% during the 3rd quarter. Barclays PLC now owns 127,668 shares of the company’s stock worth $3,662,000 after acquiring an additional 71,652 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in shares of Akero Therapeutics by 13.8% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock worth $485,000 after acquiring an additional 2,049 shares in the last quarter. XTX Topco Ltd purchased a new stake in Akero Therapeutics during the third quarter worth approximately $308,000. Finally, Wellington Management Group LLP boosted its holdings in Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares in the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.